Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with lenvatinib within its marketing authorisation for treating untreated squamous cell carcinoma of the head and neck.
Please note that following on from information provided to NICE by the company in November 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 5118
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 December 2024 | Discontinued. Please note that following on from information provided to NICE by the company in November 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued |
| 30 November 2023 | Note - Note added to the project documents |
| 31 July 2023 | Note added to the project documents |
| 08 June 2023 - 06 July 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5118 |
| 08 June 2023 | In progress. Scoping commencing |
| 04 May 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 March 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 March 2022 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual